Crossmark

Drug Persistence and Incidence of Active Tuberculosis of Tumor Necrosis Factor Alpha Inhibitors Versus Tocilizumab as the First-Line Biological Treatment in Patients with Rheumatoid Arthritis: A Nationwide Population-Based Retrospective Cohort Analysis

Crossref DOI link: https://doi.org/10.1007/s40744-024-00674-1

Published Online: 2024-05-20

Published Print: 2024-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

So, Min Wook https://orcid.org/0000-0001-5027-0410
Kim, A-Ran https://orcid.org/0000-0002-9165-8996
Lee, Seung-Geun https://orcid.org/0000-0002-5205-3978
Funding

Funding for this research was provided by:

JW Pharmaceutical
License Information

Text and Data Mining valid from 2024-05-20

Version of Record valid from 2024-05-20
More Information

Article History

Received: 13 March 2024

Accepted: 29 April 2024

First Online: 20 May 2024

Declarations

:

: Min Wook So, A-Ran Kim, and Seung-Geun Lee have declared no conflicts of interest.

: This study was approved by the Research and Ethical Review Board of Pusan National University Hospital, which waived the requirement for informed consent because of the retrospective study design and anonymity of the extracted data (IRB no. 2007-032-093).

Document is current

Any future updates will be listed below